Review of osteoporosis pharmacotherapy for geriatric patients

American Journal Geriatric Pharmacotherapy

Volumn 7, Issue 6, 2009, Pages 293-323

  Gates, Brian J ^a   Sonnett, Travis E ^a   DuVall, Cristina A K ^b   Dobbins, Erin K ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Washington State Medical Association   (United States)

Author keywords

falls; fracture; geriatric; osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTHRALGIA; ASTHENIA; BACKACHE; BONE DENSITOMETRY; BONE DENSITY; CALCIUM INTAKE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELDERLY CARE; EPISTAXIS; ESTROGEN THERAPY; ETHNIC DIFFERENCE; EXERCISE; FATIGUE; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; GENETIC DIFFERENCE; GERIATRIC PATIENT; HEADACHE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HOT FLUSH; HUMAN; INFECTION; JAW OSTEONECROSIS; LIFESTYLE MODIFICATION; MENOPAUSAL SYNDROME; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; OPTIMAL DRUG DOSE; OSTEOPOROSIS; OSTEOSARCOMA; PAIN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHINITIS; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT CONTRAINDICATION; UPPER RESPIRATORY TRACT INFECTION; VERTEBRA FRACTURE; VITAMIN INTAKE;

AGED; ALENDRONATE; BONE DENSITY; CALCITONIN; CALCIUM, DIETARY; DIPHOSPHONATES; ECONOMICS, PHARMACEUTICAL; ETIDRONIC ACID; EXERCISE; FEMALE; HUMANS; LIFE STYLE; MALE; OSTEONECROSIS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VITAMIN D;

EID: 74549123931     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2009.12.004     Document Type: Review

References (150)

1. National Osteoporosis Foundation. Osteoporosis fast facts. http://www.nof.org/professionals/Fast_Facts_Osteoporosis.pdf Accessed August 19, 2009
2. Johnell O., and Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 17 (2006) 1726-1733
3. Vanness D.J., and Tosteson A.N. Estimating the opportunity costs of osteoporosis in the United States. Topics Geriatr Rehab. 21 (2005) 4-16
4. Vestergaard P., Rejnmark L., and Mosekilde L. Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int. 18 (2007) 1583-1593
5. Tosteson A.N., Gottlieb D.J., Radley D.C., et al. Excess mortality following hip fracture: The role of underlying health status. Osteoporos Int. 18 (2007) 1463-1472
6. Kanis J.A., Johnell O., Oden A., et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 15 (2004) 20-26
7. Ray N.F., Chan J.K., Thamer M., and Melton III L.J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res. 12 (1997) 24-35
8. Kanis J.A., Oden A., Johnell O., et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int. 15 (2004) 108-112
9. Ismail A.A., O'Neill T.W., Cooper C., et al. Mortality associated with vertebral deformity in men and women: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int. 8 (1998) 291-297
10. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet. 353 (1999) 878-882
11. Kado D.M., Duong T., Stone K.L., et al. Incident vertebral fractures and mortality in older women: A prospective study. Osteoporos Int. 14 (2003) 589-594
12. Kanis J.A., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 35 (2004) 375-382
13. van Staa T.P., Leufkens H.G., and Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int. 13 (2002) 624-629
14. Manolagas S.C. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 21 (2000) 115-137
15. Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am. 32 (2003) 25-38
16. Seeman E. Invited review: Pathogenesis of osteoporosis. J Appl Physiol. 95 (2003) 2142-2151
17. Silva M.J., and Gibson L.J. Modeling the mechanical behavior of vertebral trabecular bone: Effects of age-related changes in microstructure. Bone. 21 (1997) 191-199
18. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 285 (2001) 785-795
19. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 312 (1996) 1254-1259
20. Nuti R, Brandi ML, Isaia G, et al. New perspectives on the definition and the management of severe osteoporosis: The patient with two or more fragility fractures[published online ahead of print July 17, 2009]. J Endocrinol Invest.
21. Mauck K.F., and Clarke B.L. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 81 (2006) 662-672
22. Espallargues M., Sampietro-Colom L., Estrada M.D., et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: A systematic review of the literature. Osteoporos Int. 12 (2001) 811-822
23. Drezner M.K. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav. 5 Suppl 2 (2004) S41-S47
24. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 25 (2007) 829-836
25. Valmadrid C., Voorhees C., Litt B., and Schneyer C.R. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol. 58 (2001) 1369-1374
26. Pack A.M., and Morrell M.J. Adverse effects of antiepileptic drugs on bone structure: Epidemiology, mechanisms and therapeutic implications. CNS Drugs. 15 (2001) 633-642
27. Stephen L.J., McLellan A.R., Harrison J.H., et al. Bone density and antiepileptic drugs: A case-controlled study. Seizure. 8 (1999) 339-342
28. Farhat G., Yamout B., Mikati M.A., et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 58 (2002) 1348-1353
29. US Dept of Health and Human Services, and US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: Recommendations and rationale. http://www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm Accessed August 19, 2009
30. National Osteoporosis Foundation (NOF). NOF's Clinician's Guide to Prevention and Treatment of Osteoporosis. http://www.nof.org/professionals/Clinicians_Guide.htm Accessed August 16, 2009
31. Qaseem A., Snow V., Shekelle P., et al., Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians [published correction appears in Ann Intern Med. 2008;148:888]. Ann Intern Med. 148 (2008) 680-684
32. Cadarette S.M., Jaglal S.B., Murray T.M., et al., Canadian Multicentre Osteoporosis Study. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA. 286 (2001) 57-63
33. McLeod K.M., and Johnson C.S. Identifying women with low bone mass: A systematic review of screening tools. Geriatr Nurs. 30 (2009) 164-173
34. Lydick E., Cook K., Turpin J., et al. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care. 4 (1998) 37-48
35. Cadarette S.M., Jaglal S.B., Kreiger N., et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ. 162 (2000) 1289-1294
36. Weinstein L., and Ullery B. Identification of at-risk women for osteoporosis screening. Am J Obstet Gynecol. 183 (2000) 547-549
37. Koh L.K., Sedrine W.B., Torralba T.P., et al., Osteoporosis Self-Assessment Tool for Asians (OSTA) Research Group. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int. 12 (2001) 699-705
38. Nelson H.D., Helfand M., Woolf S.H., and Allan J.D. Screening for postmenopausal osteoporosis: A review of the evidence for the US Preventive Services Task Force. Ann Intern Med. 137 (2002) 529-541
39. World Health Organization Collaborating Centre for Metabolic Bone Diseases (WHO). FRAX: WHO fracture risk assessment tool. http://www.shef.ac.uk/FRAX/index.htm Accessed August 16, 2009
40. Institute for Clinical Systems Improvement (ICSI). Preventive services for adults (guideline). http://www.icsi.org/guidelines_and_more/gl_os_prot/preventive_health_maintenance/preventive_services_for_adults/preventive_services_for_adults_11.html Accessed July 29, 2009
41. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, and Institute of Medicine. Dietary Reference Intakes: For Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride (1997), National Academy Press, Washington, DC
42. Nordin B.E. Calcium and osteoporosis. Nutrition. 13 (1997) 664-686
43. Harvey J.A., Kenny P., Poindexter J., and Pak C.Y. Superior calcium absorption from calcium citrate than calcium carbonate using external forearm counting. J Am Coll Nutr. 9 (1990) 583-587
44. Heaney R.P., Dowell M.S., and Barger-Lux M.J. Absorption of calcium as the carbonate and citrate salts, with some observations on method. Osteoporos Int. 9 (1999) 19-23
45. Spencer H., Menczel J., Lewin I., and Samachson J. Effect of high phosphorus intake on calcium and phosphorus metabolism in man. J Nutr. 86 (1965) 125-132
46. Schiller L.R., Santa Ana C.A., Sheikh M.S., et al. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med. 320 (1989) 1110-1113
47. Hallberg L., Rossander-Hultén L., Brune M., and Gleerup A. Calcium and iron absorption: Mechanism of action and nutritional importance. Eur J Clin Nutr. 46 (1992) 317-327
48. Clarkson E.M., Warren R.L., McDonald S.J., and de Wardener H.E. The effect of a high intake of calcium on magnesium metabolism in normal subjects and patients with chronic renal failure. Clin Sci. 32 (1967) 11-18
49. Jackson R.D., LaCroix A.Z., Gass M., et al., Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures [published correction appears in N Engl J Med. 2006;354:1102]. N Engl J Med. 354 (2006) 669-683
50. Shannon M.T., Wilson B.A., and Stang C.L. Health Professional's Drug Guide (2000), Appleton & Lange, Stamford, Conn
51. Fine K.D., Santa Ana C.A., Porter J.L., and Fordtran J.S. Intestinal absorption of magnesium from food and supplements. J Clin Invest. 88 (1991) 396-402
52. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 69 (1999) 842-865
53. Bischoff-Ferrari H.A. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol. 624 (2008) 55-71
54. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., et al. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA. 293 (2005) 2257-2264
55. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., et al. Effect of vitamin D on falls: A meta-analysis. JAMA. 291 (2004) 1999-2006
56. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride (1997), National Academy Press, Washington, DC
57. 2) therapy. A case report and literature review. South Med J. 102 (2009) 765-768
58. Moon J. The role of vitamin D in toxic metal absorption: A review. J Am Coll Nutr. 13 (1994) 559-564
59. Gregg E.W., Pereira M.A., and Caspersen C.J. Physical activity, falls, and fractures among older adults: A review of the epidemiologic evidence. J Am Geriatr Soc. 48 (2000) 883-893
60. Bonaiuti D., Shea B., Iovine R., et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 3 (2002) CD000333
61. Gillespie L.D., Robertson M.C., Gillespie W.J., et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2 (2009) CD007146
62. National Osteoporosis Foundation. Health Professional's Guide to Rehabilitation of the Patient with Osteoporosis. http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf Accessed July 29, 2009
63. Krall E.A., and Dawson-Hughes B. Smoking increases bone loss and decreases intestinal calcium absorption. J Bone Miner Res. 14 (1999) 215-220
64. Tucker K.L., Jugdaohsingh R., Powell J.J., et al. Effects of beer, wine, and liquor intakes on bone mineral density in older men and women. Am J Clin Nutr. 89 (2009) 1188-1196
65. Macdonald H.M., New S.A., Golden M.H., et al. Nutritional associations with bone loss during the menopausal transition: Evidence of a beneficial effect of calcium, alcohol, and fruit and vegetable nutrients and of a detrimental effect of fatty acids. Am J Clin Nutr. 79 (2004) 155-165
66. Hirsch P.E., and Peng T.C. Effects of alcohol on calcium homeostasis and bone. In: Anderson J.J., and Garner S.C. (Eds). Calcium and Phosphorus in Health and Disease (1996), CRC Press, Boca Raton, Fla
67. US Dept of Agriculture. Results from the United States Department of Agriculture's 1994-96 Continuing Survey of Food Intakes by Individuals/Diet and Health Knowledge Survey (1994-1996)
68. Kogawa M., and Wada S. Osteoporosis and alcohol intake [in Japanese]. Clin Calcium. 15 (2005) 102-105
69. Russell R.G. Bisphosphonates: From bench to bedside. Ann N Y Acad Sci. 1068 (2006) 367-401
70. Russell R.G., Watts N.B., Ebetino F.H., and Rogers M.J. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 19 (2008) 732-759
71. Russell R.G., Mühlbauer R.C., Bisaz S., et al. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res. 6 (1970) 183-196
72. Dunford J.E., Thompson K., Coxon F.P., et al. Structureactivity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 296 (2001) 235-242
73. Kavanaugh K.L., Guo K., Dunford J.E., et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 103 (2006) 7829-7834
74. Luckman S.P., Hughes D.E., Coxon F.P., et al. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 13 (1998) 581-589
75. Drake M.T., Clarke B.L., and Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc. 83 (2008) 1032-1045
76. Liberman U.A., Weiss S.R., Bröll J., et al., Alen-dronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333 (1995) 1437-1443
77. Black D.M., Cummings S.R., Karpf D.B., et al., Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 348 (1996) 1535-1541
78. Black D.M., and Thompson D.E. The effect of alendronate therapy on osteoporosis fracture in the vertebral fracture arm of the Fracture Intervention Trial. Int J Clin Pract. Suppl. 101 (1999) 46-50
79. Cranney A., Wells G., Willan A., et al., Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 23 (2002) 508-516
80. Harris S.T., Watts N.B., Genant H.K., et al., Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonver-tebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA. 282 (1999)
81. Reginster J., Minne H.W., Sorenson O.H., et al., Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 11 (2000) 83-91
82. McClung M.R., Geussens P., Miller P.D., et al., Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 344 (2001) 333-340
83. Boonen S., McClung M.R., Eastell R., et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 52 (2004) 1832-1839
84. Chesnut III C.H., Skag A., Christiansen C., et al., Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 19 (2004) 1241-1249
85. Black D.M., Delmas P.D., Eastell R., et al., HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 356 (2007) 1809-1822
86. Lyles K.W., Colön-Emeric C.S., Magaziner J.S., et al., HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 357 (2007) 1799-1809
87. Ettinger B., Black D.M., Mitlak B.H., et al., Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial [published correction appears in JAMA. 1999;282:2124]. JAMA. 282 (1999) 637-645
88. Ensrud K.E., Stock J.L., Barrett-Connor E., et al. Effects of raloxifene on fracture risk in postmenopausal women: The Raloxifene Use for the Heart Trial. J Bone Miner Res. 23 (2008) 112-120
89. Chesnut III C.H., Silverman S., Andriano K., et al., PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fracture study. Am J Med. 109 (2000) 267-276
90. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344 (2001) 1434-1441
91. Rizzoli R., Greenspan S.L., Bone III G., et al., Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 17 (2002) 1988-1996
92. Agrawal S., Krueger D.C., Engelke J.A., et al. Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc. 54 (2006) 790-795
93. Brown J.P., Kendler D.L., McClung M.R., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 71 (2002) 103-111
94. Ste-Marie L.G., Brown J.P., Beary J.F., et al. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. Clin Ther. 31 (2009) 272-285
95. Eisman J.A., Civitelli R., Adami S., et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-Year results from the DIVA study. J Rheumatol. 35 (2008) 488-497
96. Reclast (zoledronic acid) [package insert] (May 2009), Novartis Pharmaceuticals Corp, East Hanover, NJ
97. Fosamax (alendronate) [package insert] (2008), Merck & Co, Inc, Whitehouse Station, NJ
98. Actonel (risedronate sodium) [package insert] (2008), Procter & Gamble Pharmaceuticals, Inc, Cincinnati, Oh
99. Boniva (ibandronate sodium) [package insert] (2008), Roche Laboratories Inc, Nutley, NJ
100. Watts N.B., and Marciani R.D. Osteonecrosis of the jaw. South Med J. 101 (2008) 160-165
101. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 353 (2005) 99-100 discussion
102. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 353 (2005) 99-102
103. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 23 (2005) 8580-8587
104. Mavrokokki T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 65 (2007) 415-423
105. Khosla S., Burr D., Cauley J., et al., American Society for Bone and Mineral Research. Bisphosphonateassociated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 22 (2007) 1479-1491
106. Bilezikian J.P. Osteonecrosis of the jaw-do bisphosphonates pose a risk?. N Engl J Med. 355 (2006) 2278-2281
107. Woo S.B., Hellstein J.W., and Kalmar J.R. Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006;145:235]. Ann Intern Med. 144 (2006) 753-761
108. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonateinduced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 65 (2007) 2397-2410
109. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc. 137 (2006) 1144-1150
110. Cummings S.R., Schwartz A.V., and Black D.M. Alendronate and atrial fibrillation. N Engl J Med. 356 (2007) 1895-1896
111. Heckbert S.R., Li G., Cummings S.R., et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 168 (2008) 826-831
112. Jensen E.V., and Jordan V.C. The estrogen receptor: A model for molecular medicine. Clin Cancer Res. 9 (2003) 1980-1989
113. Yang N.N., Venugopalan M., Hardikar S., and Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene [published correction appears in Science. 1997;275:1249]. Science. 273 (1996) 1222-1225
114. Delmas P.D., Genant H.K., Crans G.C., et al. Severity of prevalent fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial. Bone. 33 (2003) 522-532
115. Riggs B.L., and Hartmann L.C. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice [published correction appears in N Engl J Med. 2003;348:1192]. N Engl J Med. 348 (2003) 618-629
116. Evista (raloxifene hydrochloride) [prescribing information] (2008), Eli Lilly and Company, Indianapolis, Ind
117. Karsdal M.A., Henriksen K., Arnold M., and Christiansen C. Calcitonin: A drug of the past or future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. Bio Drugs. 22 (2008) 137-144
118. Chesnut III C.H., Majumdar S., Newitt D.C., et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: Results from the QUEST study. J Bone Miner Res. 20 (2005) 1548-1561
119. Miacalcin (calcitonin-salmon) [package insert] (2002), Novartis Pharmaceuticals Corp, East Hanover, NJ
120. Forteo (teriparatide) [package insert] (2008), Eli Lilly and Company, Indianapolis, Ind
121. Boonen S., Marin F., Mellstrom D., et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc. 54 (2006) 782-789
122. Minne H., Audran M., Sim{eth}es M.E., et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: One-year results from the EUROFORS study. Curr Med Res Opin. 24 (2008) 3117-3128
123. Obermayer-Pietsch B.M., Marin F., McCloskey E.V., et al., EUROFORS Investigators. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 23 (2008) 1591-1600
124. Miller P.D. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 6 (2008) 12-16
125. Premarin (conjugated estrogens) [package insert] (2008), Wyeth Pharmaceuticals, Inc, Philadelphia, Pa
126. Cauley J.A., Robbins J., Chen Z., et al., Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA. 290 (2003) 1729-1738
127. Cadarette S.M., Katz J.N., Brookhart M.A., et al. Relative effectiveness of osteoporosis drugs for preventing non-vertebral fracture. Ann Intern Med. 148 (2008) 637-646
128. Silverman S.L., Watts N.B., Delmas P.D., et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study. Osteoporos Int. 18 (2007) 25-34
129. Watts N.B., Cooper C., Lindsay R., et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 7 (2004) 255-261
130. Sebba A.I., Emkey R.D., Kohles J.D., and Sambrook P.N. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis. Bone. 44 (2009) 423-427
131. Hochberg M.C., Greenspan S., Wasnich R.D., et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 87 (2002) 1586-1592
132. Sambrook P.N., Geusens P., Ribot C., et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: Results of EFFECT (Efficacy of Fosamax versus Evista Comparison Trial) international. J Intern Med. 255 (2004) 503-511
133. Rosen C.J., Hochberg M.C., Bonnick S.L., et al., Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized doubleblind study. J Bone Miner Res. 20 (2005) 141-151
134. Emkey R., Delmas P., Bolognese M., et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) study. Clin Ther. 31 (2009) 751-761
135. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 Position statement of The North American Menopause Society. Menopause. 13 (2006) 340-367 quiz
136. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 Position statement of The North American Menopause Society. Menopause. 13 (2006) 368-369
137. Cosman F., Wermers R.A., Recknor C., et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: Differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 94 (2009) 3772-3780
138. Black D.M., Greenspan S.L., Ensrud K.E., et al., PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 349 (2003) 1207-1215
139. Black D.M., Bilezikian J.P., Ensrud K.E., et al., PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 353 (2005) 555-565
140. Liu H., Michaud K., Nayak S., et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 166 (2006) 1209-1217
141. Tosteson A.N., Burge R.T., Marshall D.A., and Lindsay R. Therapies for treatment of osteoporosis in US women: Cost-effectiveness and budget impact considerations. Am J Manag Care. 14 (2008) 605-615
142. Fleurence R.L., Iglesias C.P., and Johnson J.M. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: A structured review of the literature. Pharmaco Economics. 25 (2007) 913-933
143. Tosteson A.N., Melton III L.J., Dawson-Hughes B., et al., National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: The United States perspective. Osteoporos Int. 19 (2008) 437-447
144. Massart F., Marcucci G., and Brandi M.L. Pharmacogenetics of bone treatments: The VDR and ERalpha gene story. Pharmacogenomics. 9 (2008) 733-746
145. Pillai G., Gieschke R., Goggin T., et al. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. Int J Clin Pharmacol Ther. 44 (2006) 655-667
146. Wasnich R.D., Ross P.D., Thompson D.E., et al. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. Osteoporos Int. 9 (1999) 455-460
147. Barnato S., and Sprague S.M. Advances in renal bone disease: Osteoporosis and chronic kidney disease. Curr Rheumatol Rep. 11 (2009) 185-190
148. Ettinger B., Pressman A., and Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care. 4 (1998) 1377-1382
149. Stevenson M., Jones M.L., De Nigris E., et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 9 (2005) 1-160
150. Qaseem A., Snow V., Shekelle P., et al., Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 149 (2008) 404-415